A new study published in Natural Product Research reports that two rare varin-type cannabinoids may offer meaningful anticancer potential, with researchers identifying strong cytotoxic effects in breast and colon cancer cell lines.
The work was conducted by a team at the Indian Institute of Integrative Medicine, who developed a method to generate hard-to-access cannabinoids from more common cannabis compounds.
The researchers used an extract engineering approach to create nine cannabinoid analogues, including four that belong to the varin family, which naturally occur only in trace amounts in the plant. By synthesizing these compounds in the lab, the team was able to evaluate their activity across five human cancer cell lines. Two stood out sharply: cannabinovarin (CBNV) and Δ6a,10a-THCV. Both produced notable cytotoxic responses in breast cancer (MCF-7) and colon cancer (HCT-116) cells, with IC50 values measured between 15 and 30 µM.
Further analysis pointed to apoptosis as a primary mechanism. The compounds disrupted mitochondrial membrane integrity and increased the production of reactive oxygen species, both key steps in programmed cell death. The findings suggest that engineered extracts could provide a reliable way to study rare cannabinoids that are otherwise difficult to obtain, while positioning CBNV and Δ6a,10a-THCV as promising candidates for deeper mechanistic research and eventual in vivo testing.
